Repatha 140 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26FV7U6
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $6,211
Award facts
- Contract value 100% obligated
- $6,211.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $6,211.30 delivery order to AmerisourceBergen Drug Corp on January 16, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a task order executed under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical. The IDC, valued at up to $999,999,999.00 through December 2031, serves as the primary vehicle for supplying a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract was competitively awarded with no set-aside designation, demonstrating AmerisourceBergen's capability to meet federal procurement requirements through open competition. Performance will be completed at the contractor's facility in Conshohocken, Pennsylvania.
Repatha (evolocumab) is a PCSK9 inhibitor utilized for cardiovascular disease management, particularly for patients with familial hypercholesterolemia or established cardiovascular disease who require additional LDL cholesterol reduction. This delivery order supports the Defense Health Agency and broader military healthcare systems in providing essential pharmaceutical therapeutics to service members and beneficiaries. AmerisourceBergen's substantial federal contract portfolio across DLA and other agencies reflects its established position as a critical vendor in the federal medical supply chain, with extensive experience distributing specialty medications, biologics, and medical devices across multiple therapeutic domains to government healthcare systems.
Quick answers
Who was awarded contract SPE2DR26FV7U6?
SPE2DR26FV7U6 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26FV7U6 worth?
The government has obligated $6,211 on SPE2DR26FV7U6.
Is contract SPE2DR26FV7U6 an order under another contract?
Yes. SPE2DR26FV7U6 is a delivery order under SPE2DR25D2214, an indefinite delivery contract.
Was contract SPE2DR26FV7U6 competed?
The extent of competition for SPE2DR26FV7U6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award